Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
39.2M
-
Shares change
-
+4.64M
-
Total reported value, excl. options
-
$406M
-
Value change
-
+$49M
-
Number of buys
-
28
-
Number of sells
-
-25
-
Price
-
$10.38
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q3 2019
72 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q3 2019.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.2M shares
.
Largest 10 shareholders include FMR LLC (6.13M shares), Nikko Asset Management Americas, Inc. (4.63M shares), Sumitomo Mitsui Trust Holdings, Inc. (4.63M shares), Redmile Group, LLC (3.89M shares), ARK Investment Management LLC (3.83M shares), Flagship Pioneering Inc. (2.94M shares), BlackRock Inc. (2.74M shares), VANGUARD GROUP INC (1.8M shares), Samsara BioCapital, LLC (1.73M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.27M shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.